
|
Loading...
Loading...
|
US Pharm. 2011;36(10):8.
Gaithersburg, MD—The FDA has announced that OTC epinephrine inhalers containing chlorofluorocarbons (CFCs) cannot be made or sold after December 31, 2011. Primatene Mist, marketed by Armstrong Pharmaceutical Inc., is the only nonprescription inhaler that uses CFCs as a propellant. This action is being taken to comply with an international agreement to phase out substances, such as CFCs, that deplete the ozone layer. Many manufacturers have already replaced their CFC inhalers with hydrofluoroalkane (HFA), an environmentally-friendly propellant. Current users of Primatene Mist should plan to get a prescription for a replacement product to relieve their asthma symptoms. The product currently carries a prominent notice about the phase-out date on its label.
To comment on this article, contact
rdavidson@uspharmacist.com.
|
Loading...
Loading...
|
|
U.S. Pharmacist is a monthly journal dedicated to providing the nation's pharmacists with up-to-date,
authoritative, peer-reviewed clinical articles relevant to contemporary pharmacy practice in a variety of settings,
including community pharmacy, hospitals, managed care systems, ambulatory care clinics, home care organizations,
long-term care facilities, industry and academia. The publication is also useful to pharmacy technicians, students,
other health professionals and individuals interested in health management. Pharmacists licensed in the U.S. can earn
Continuing Education credits through Postgraduate Healthcare Education, LLC, accredited by the Accreditation Council for Pharmacy Education (ACPE)
as a provider of continuing pharmacy education.
Copyright © 2000 - 2013 Jobson Medical Information LLC unless otherwise noted.
All rights reserved. Reproduction in whole or in part without permission is prohibited.
|